Bleeding events | Rivaroxaban group | Parnaparin group | P value |
---|---|---|---|
Any bleeding during the treatment | 21 (6.2 %) | 17 (5.2 %) | >0.5 |
Severe bleeding | 2 (0.6 %) | 1 (0.3 %) | >0.25* |
Fatal bleeding | 0 | 0 | Â |
Bleeding into important organs | 1 | 0 | Â |
Reoccurrence of surgical bleeding | 1 | 0 | Â |
Clinically obvious bleeding outside the surgical site | 0 | 1 | Â |
Induced hemoglobin decreasing | 0 | 0 | Â |
Induced blood transfusion ≥2 units | 0 | 0 |  |
Non-severe bleeding | 19 (5.6 %) | 16 (4.9 %) | >0.5 |
Clinically related non-severe bleedinga | 6 | 6 | Â |
Bleeding incision complicationsb | 7 | 4 | Â |
Other non-severe bleeding | 6 | 6 | Â |